Ra Pharmaceuticals Inc. (Nasdaq: RARX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO

ADVISORY, Oct. 27, 2016 --

What:  
Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).

In honor of the occasion, Douglas Treco, Ph.D., Chief Executive Officer and Co-Founder, will ring the Opening Bell. 

Where: 
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When: 
Thursday, October 27, 2016 – 9:15 a.m. to 9:30 a.m. ET 

Ra Pharmaceuticals Media Contact: 
Eliza Schleifstein
(917) 763-8106 
[email protected]

Nasdaq MarketSite: 
Emily Pan
(646) 441-5120 
[email protected]

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media: 
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: 
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page: 
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page: 
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page: 
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page: 
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About Ra Pharmaceuticals 
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of nextgeneration therapeutics for diseases of complement dysregulation and for orphan indications. The Company utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. Derived from its proprietary Extreme Diversity™ peptide chemistry platform, RA101495 is a macrocyclic peptide inhibitor of complement C5, and is currently in Phase 1 development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). For more information, please visit: www.rapharma.com.

About Nasdaq 
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-